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Abstract
T cells are key mediators of graft tolerance/rejection, development of autoim-
munity, and the anticancer response. Consequently, differentially modifying the 
T cell response is a major therapeutic target. Most immunomodulatory approaches 
have focused on cytotoxic agents, cytokine modulation, monoclonal antibodies, 
mitogen activation, adoptive cell therapies (including CAR-T cells). However, 
these approaches do not persistently reorient the systemic immune response thus 
necessitating continual therapy. Previous murine studies from our laboratory 
demonstrated that the adoptive transfer of polymer-grafted (PEGylated) allogeneic 
leukocytes resulted in the induction of a persistent and systemic tolerogenic state. 
Further analyses demonstrated that miRNA isolated from the secretome of polymer- 
modified or control allogeneic responses effectively induced either a tolerogenic 
(TA1 miRNA) or proinflammatory (IA1 miRNA) response both in vitro and in vivo 
that was both systemic and persistent. In a murine Type 1 diabetes autoimmune 
model, the tolerogenic TA1 therapeutic effectively attenuated the disease process via 
the systemic upregulation of regulatory T cells while simultaneously downregulat-
ing T effector cells. In contrast, the proinflammatory IA1 therapeutic enhanced 
the anticancer efficacy of naïve PBMC by increasing inflammatory T cells and 
decreasing regulatory T cells. The successful development of this secretome miRNA 
approach may prove useful treating both autoimmune diseases and cancer.
Keywords: T lymphocyte, miRNA, polymer, secretome, tolerance, Treg, 
proinflammatory, Teff, autoimmunity, cancer, adoptive cell transfer
1. Introduction
Biologically, and clinically, the concept of “self” is of crucial importance in pro-
tection against foreign biologicals (e.g., viruses and bacteria), abnormal autologous 
cells (e.g., cancers) and more recently developed “diseases” (i.e., the purposeful 
introduction of “nonself”) such as enzyme-replacement therapy and transfusion 
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Figure 1. 
Immune modulation via pharmacologic and immunocamouflage therapy. (A) Current pharmacologic therapy 
almost exclusively targets T cell activation and proliferation consequent to allorecognition. Response to nonself is 
in large part mediated by cell-cell interactions between antigen presenting cells (APC; e.g., dendritic cells) and 
naive T cells. This cell-cell interaction is characterized by essential adhesion, allorecognition and co-stimulation 
events. Consequent to allorecognition, a proliferation of proinflammatory T cells (e.g., cytotoxic T lymphocyte, 
CTL; Th17, IL-17+; Th1, IFN-γ+; and IL-2+ populations) and decrease in regulatory T cells (Treg, Foxp3+ and 
CD25+) is observed. Current therapeutic agents are primarily cytotoxic agents preventing T cell activation 
(e.g., cyclosporine and rapamycin) or T cell proliferation (e.g., methotrexate, corticosteroids and azathioprine). 
Additionally, blocking antibodies have been investigated. Gray text indicates current techniques to prevent/
limit alloimmune responses. (B) In contrast, immunocamouflage of donor cells by methoxy(polyethylene) 
glycol (mPEG) results in the disruption of the essential cell-cell interactions decreasing T cell proliferation 
and altering differentiation patterns (decreased Th17 and increased Treg). In aggregate, the polymer induced 
changes induces a tolerogenic/anergic state both in vitro and in vivo. Size of T cell population denotes increase 
or decrease in number. Size of B cell indicates antibody response. Blue text represents the consequences of 
polymer-mediated immunocamouflage of the alloresponse. (C) As shown in photomicrographs, in a control 
mixed lymphocyte reaction (MLR), significant and persistent interactions (black arrows) occur between 
allogeneic lymphocytes (LYM) and dendritic cells (APC). The lymphocyte adhesion and antigen presentation 
interactions typically occur at pseudopodal extensions from the APC (white arrows). PEGylation of either 
allogeneic PBMC population decreases the stability and duration of initial cell:cell interactions between 
lymphocytes due to the global charge and steric camouflage of membrane proteins. (D) Importantly, the 
secretomes derived from the MLR and mPEG-MLR exert potent effects on a secondary MLR encompassing 
fresh PBMC from the same or different donors. The key component of the secretome are soluble (free and 
exosome) miRNA. Data derived from Refs [32–43].
and transplantation medicine. The immune system is tasked with preserving 
“self” and rejecting “nonself” and has multiple components-any of which will be 
of variable importance depending on the context of the immunological assault. 
Immunological “self” of most tissues is imparted by the major histocompatibility 
complex (MHC) which encodes a variety of proteins that provide a means for 
identifying, targeting, and eliminating foreign invaders and diseased cells while pre-
serving normal “self” tissue. The MHC proteins themselves consist of three classes. 
MHC Class I molecules are expressed on virtually all nucleated cells while Class II 
molecules are expressed exclusively on antigen presenting cells (APC; e.g., mono-
cytes, macrophages, dendritic cell, B lymphocytes, and endothelial cells) and acti-
vated T lymphocytes. MHC Class III genes encode components of the complement 
system. The human MHC is referred to as the Human Leukocyte Antigen (HLA) 
complex while the murine equivalent is referred to as the Histocompatibility-2 (H2) 
complex. In the context of MHC-mediated immune recognition, the T lymphocyte 
(T cell) is of particular importance. T cells themselves consist of a diverse array 
of subsets that fall into two general categories: 1) Regulatory T cells (Treg) which 
modulate the strength of an immune response and maintain “self”; and effector T 
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cells (Teff) that mediate the inflammatory response and consists, in part, of Th1, 
Th17 and Th2 subsets. Hence, the functional ratio of Treg to Teff (Treg:Teff) cells is 
critical and an imbalance of this ratio from the norm can induce either an autoim-
mune (excess Teff or decreased Treg) state or impaired response to “nonself” (e.g., 
cancer) consequent to biologically ill-advised tolerance (too many Treg or weak Teff 
response). Indeed, the T cell response plays a (the) central role in autoimmune dis-
eases, transplant rejection, graft versus host disease (GVHD), graft versus leukemia 
(GVL), cancer and, more recently, cancer therapy. Hence, consequent to the central 
role of T cells as a key cellular component in the development of autoimmune dis-
eases, graft tolerance or rejection, and the anticancer response, the T cell response 
has been a major focus in the development of clinical therapies (Figure 1A) [1].
2.  Immunomodulation of the T cell response in autoimmunity and 
cancer
Autoimmune diseases arise when the immune system recognizes the individual’s 
own tissues or organs as “foreign” and targets them for destruction. Autoimmune 
diseases can affect virtually all tissues and organ systems and encompass such 
diverse diseases as Type 1 Diabetes (T1D; pancreas), Idiopathic Thrombocytopenic 
Purpura (ITP; platelet destruction), Crohn’s disease (CD; bowel), Multiple Sclerosis 
(MS; brain) and Rheumatoid Arthritis (RA; joints). Despite the diversity of tissues 
affected, extensive research has demonstrated that Treg are downregulated while Teff 
are upregulated (i.e., leading to a reduced Treg:Teff ratio) leading to a chronic proin-
flammatory state. Current therapeutic approaches to managing autoimmune diseases 
are typically focused on symptom relief and the use of immunosuppressive agents 
capable of inhibiting the proinflammatory response arising from “self-recognition.” 
Most commonly, treatment for chronic autoimmune disease is via administration of 
systemic steroids (e.g., dexamethasone), cytotoxic anti-proliferative/activation agents 
(e.g., cyclosporine) that induce a general immunosuppression, and/or IVIG (pooled, 
polyvalent, IgG purified from the plasma of >1000 blood donors) [2–6]. Other 
experimental approaches to the treatment of autoimmune diseases include blocking 
monoclonal antibodies directed against the TCR, CD4, costimulatory ligands and 
receptors, adhesion molecules, and cytokine receptors [7–9]. A more recent approach 
has been to interrupt the cytokine signals necessary for the activation and prolifera-
tion of autoreactive T cells. The current gold standard for this approach is Enbrel® 
(etanercept), a solubilized TNF-α receptor fragment that intercepts and sequesters 
the TNF-α cytokine thereby inhibiting the proliferation of proinflammatory T cells 
[10–15]. However, Enbrel® has been given a USA FDA “Black Box” warning due 
to significantly increased risks of serious infections that may lead to hospitaliza-
tion or death [16–22]. Common to all of these approaches is an attempt to increase 
the Treg:Teff ratio by either directly increasing Treg or selectively decreasing Teff 
populations. However, despite their importance in clinical medicine, many of these 
agents have been plagued by both significant toxicity/adverse events and an inability 
to adequately eliminate or inhibit reactive T cells [8].
In contrast to autoimmune diseases, an insufficient/inefficient immune response 
may underlie the proliferation and dissemination of abnormal cells (i.e., cancer 
cells). While this may occur for a number of reasons, immunosuppression is a 
known risk factor. Indeed, acquired or inherited T cell defects as well as long-term 
therapy with immunosuppressive drugs are clearly associated with an increased 
risk of neoplasia. The impaired immune response to cancer cells can arise, at least 
in part, from an increase in the Treg:Teff ratio (too many Treg and/or insufficient 
Teff cell production). To address this imbalance in the Treg:Teff ratio, experimental 
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therapies are currently focused on the ex vivo expansion and subsequent transfu-
sion of autologous Teff capable of killing the cancer cells [23–31]. However, these 
current immune enhancing methods, while promising, are expensive, complicated 
to accomplish (e.g., insertion of specific target cancer genes in APC) and requires 
weeks of tissue culture expansion to meet the threshold for cell infusion.
Perhaps most importantly, current tolerogenic or proinflammatory therapeutic 
approaches fail to persistently reorient the systemic T cell immune response thus 
necessitating continual therapy. Moreover, despite the importance of the Treg:Teff 
ratio, in both autoimmune diseases and cancer, there are a paucity of pharmacologic 
tools that can directly, and in tandem, target the regulation of both the Treg and 
Teff subsets. Hence, to diminish or overcome the need for chronic administration of 
immunotherapeutic agents, new approaches capable of persistently reorienting the 
endogenous immune (Treg:Teff) response would be of value.
3.  Immunomodulation via immunocamouflage and differential miRNA 
production
Previous studies from our laboratory demonstrated that a persistent and 
systemic reorientation of the animal (murine; or in vitro human) immune 
response towards a tolerogenic response could be induced via the adoptive 
transfer of immunocamouflaged allogeneic leukocytes to a recipient animal 
[32–43]. Immunocamouflage of cells is mediated by the covalent grafting of 
methoxypoly(ethylene glycol) (mPEG) to the leukocyte membrane surface. 
Consequent to mPEG-grafting (PEGylation), MHC-mediated T cell alloprolifera-
tion is dramatically inhibited due to consequent to impaired cell:cell interaction 
and weak allostimulation (Figure 1A and B). These studies demonstrated that the 
PEGylated allogeneic leukocytes diminished intracellular communication pre-
venting a Teff response while simultaneously inducing the generation of Treg cells 
skewing the Treg:Teff ratio towards a tolerogenic state (Figure 1B and C)  
[36, 38–43]. Further in vitro and in vivo studies demonstrated that, using 
MLR-based secretome biomanufacturing systems, distinct acellular microRNA 
(miRNA) based therapeutics could be manufactured from control and PEGylated 
allorecognition reactions that systemically and persistently reorient the immune 
response to either a proinflammatory (IA1) or tolerogenic (TA1) state (Figure 1) 
[40, 43]. In this chapter, we will demonstrate how these miRNA-based therapeu-
tics can inhibit the progression of T cell mediated autoimmune diseases (TA1) or 
conversely enhance the proinflammatory anticancer T cell response (IA1).
4. Production of miRNA therapeutics via the alloresponse pathway
Since their discovery in 1996, the role of circulating (cell-free) miRNA in disease 
processes has become an active research area and recent findings suggest that they 
may be biomarkers, or possibly mediators, of cancers as well as autoimmune diseases 
such as T1D [44–46]. To understand mechanistically how the TA1 and IA1 miRNA 
biologics function, an appreciation of the biological role and regulatory complexity of 
miRNA is needed. Recent studies have demonstrated that miRNA are key epigenetic 
regulators of cellular processes including immune responses, inflammation, prolifera-
tion, survival, and cellular differentiation [47, 48]. miRNA are short (~22 nucleo-
tides) single-stranded RNA molecules found in all eukaryotes and it is estimated that 
~60% of mammalian genes are targeted by one or more miRNA [49, 50]. Moreover, 
because of their evolutionary importance in gene regulation, miRNA and their 
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sequence and processing are highly conserved between mammalian species  
(e.g., mouse and human) [49]. While miRNA are most commonly found intracellularly, 
significant amounts of stable miRNA are also found in the serum of mammals sug-
gesting an important messenger/regulatory role. While the nomenclature of miRNAs 
is relatively straightforward it is important to note that similarities in miRNA number 
designation is not indicative of similarity in functionality (Figure 2). Moreover, the 
literature is replete with conflicting claims for the specific actions of a single miRNA.
Indeed, there is a significant lack of clarity regarding the function of a single 
miRNA. This lack of functional clarity likely arises consequent to the complexity 
and low fidelity of the miRNA bioregulatory process. Of note, a single miRNA can 
potentially affect tens to hundreds of genes and individual genes can be regulated 
by multiple miRNA [50]. Hence, the effect of modifying the expression of a single 
miRNA on protein regulation and bioregulatory networks is unpredictable. Because 
of this regulatory complexity, most studies have focused on miRNA as disease 
biomarkers, not as therapeutic agents as there is a low probability that altered 
expression of a single, or even a few, miRNA would exert a potent and definitive 
biological response [51–54]. From a bioregulatory approach, it is more probable that 
multiple miRNA control protein expression, proliferation and differentiation and 
it is this “pattern of miRNA expression” (encompassing increased, decreased and 
static levels) that must be mimicked to achieve pharmacologically effective miRNA-
based therapeutics. To achieve this goal our laboratory approach has been purpose-
fully chosen to biologically manufacture relatively complex miRNA preparations 
mimicking normal biology in order to achieve maximal biological functionality.
Using a Mixed Lymphocyte Reaction (MLR) production model the T cell cen-
tric proinflammatory IA1 and tolerogenic TA1 therapeutics can be reproducibly 
manufactured using the control-MLR and mPEG-MLR (respectively; Figure 1). As 
demonstrated, the allogeneic PBMC populations within the control- and mPEG-
MLR express significantly different patterns of miRNA expression relative to resting 
Figure 2. 
miRNA nomenclature explained. An important concept to understand is that the miRNA number (e.g., 123 as 
shown) has no relationship to function or structure. For example, “hsa-miR-123” has no implied structural or 
functional similarity to “hsa-miR-128.” However, because of the highly conserved nature of miRNA, human 
“hsa-miR-123” has very similar structure and function to murine “mmu-miR-123.”
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PBMC as evidenced via clustergram (Figure 3A), volcano plot (Figure 3B) and Log2 
Fold (Figure 3C) miRNA expression analyses. Importantly, as shown in Figure 3C,  
the control- and mPEG-MLRs show unique patterns of expression. While there 
are some similarities in the pattern of expression there are significant disparity in 
miRNAs expressed as well (not shown are the miRNA unchanged from resting cells).
Importantly, the differences in miRNA expression between the Control- and 
mPEG-MLR leukocyte yield secretomes that exert dramatically different effects 
when used to treat resting human PBMC or murine splenocytes. Collection of 
the secretome produced (Figure 4A) during the control and polymer modified 
allorecognition-based MLR yields a reproducible, acellular, miRNA-rich, material 
that is stable and can be frozen and thawed with minimal decrement to its activity. As 
schematically presented (Figure 4B), TA1 upregulates regulatory T cell populations 
(e.g., Treg) while simultaneously downregulating Teff (e.g., Th17 and Th1) cells. 
In contrast, the proinflammatory IA1 increases Teff while decreasing Treg cells. Of 
note, the secretome from resting cells (SYN) has minimal to no effect on human or 
mouse immune cells. Moreover, due to the conserved nature of mammalian miRNA, 
cross species efficacy is observed with both TA1 and IA1. As shown in Figure 4C, 
murine splenocyte produced TA1 and IA1 exerted dose-dependent effects on a 
human MLR with murine-sourced TA1 reducing CD3+CD4+ T cell proliferation and 
the murine IA1 enhancing CD3+CD4+ T cell proliferation. Hence, a polymer-based, 
alloresponse manufacturing system may provide a unique avenue for more effec-
tively, and safely, modulating the Treg:Teff cell ratio via the production of therapeu-
tically effective TA1 and IA1 miRNA-based therapeutics [32–43]. Importantly, the 
effects of TA1 and IA1 immunotherapy was persistent. In murine studies, a single 
dosing of TA1 to mice resulted in significant increase in Treg cells within the spleen 
of normal mice that persisted to ≥270 days post treatment (Figure 4D).
Figure 3. 
Partial qPCR characterization of the miRNA expression in the Control- and mPEG-MLR. (A–C) Clustergram 
(A), Volcano Plot (B) and Log2 Fold (C) analyses of the miRNA expression in the mPEG-MLR and 
Control-MLR relative to resting cells. (C) Because of the complexity of miRNA regulation of genes, we have 
consciously chosen to produce a relatively complex miRNA preparations mimicking normal biology in order to 
achieve maximal biological functionality. Multiple miRNA changes are noted in the hTA1 miRNA compared 
to either resting cells (green dashed line = 0) or the proinflammatory hIA1 miRNA preparation. Using miRNA 
expressing a net ΔLog2 Fold change, significantly different “patterns of expression” are noted between the hTA1 
and hIA1 miRNA. This pattern of expression, comprising both INCREASED and DECREASED miRNA 
species is essential for effective immunomodulation of recipient animals. Values derived from a minimum of 3 
independent biological replicates. Unpublished data.
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5. Tolerogenic TA1: immunomodulation of autoimmune disease
Autoimmune destruction of pancreatic islets gives rise to T1D and occurs via T 
cell dependent pathways [55–57]. Elucidation of the role of T cells in T1D has been 
most effectively examined in the nonobese diabetic (NOD) mouse model. In the 
NOD mouse, evidence suggests that a deficit in Treg control over diabetogenic Teff 
cells leads to the development of insulitis and disease [56–66]. Indeed, changes 
in the Treg:Teff ratio (i.e., balance) can be observed as early as 3–4 weeks of age 
and becomes more pronounced with disease progression (Figure 5) [56]. Human 
studies have similarly demonstrated that T1D Treg exhibit an impaired ability to 
suppress Teff [67]. Thus, the emergence of an aggressive diabetogenic lymphocyte 
response in NOD mice, and likely humans, is dependent upon a change in the 
Treg:Teff ratio.
As demonstrated in Figure 5, the Treg:Teff ratio (defined as the ratio of Foxp3+ 
to Th17+ T cells) in control (saline treated) NOD mice decreased with disease 
progression from 103 in nondiabetic 7 week old mice to only 4.7 in diabetic mice 
at time of sacrifice (15–30 week). Moreover, control NOD mice exhibited a rapid 
onset of diabetes with 75% (12 of 16) of the mice becoming diabetic by week 19. 
Subsequent to week 19, no additional mice became diabetic. In contrast, a single 
dosing (3 injections at 2 days intervals) of the TA1 therapeutic at 7 weeks of age 
dramatically altered both the incidence and rate of progression of the T1D in 
the NOD mouse. By week 19 only 13% (2 of 15) of the TA1 treated mice became 
diabetic with an additional 4 mice becoming diabetic between weeks 21 and 23 
(total diabetic 6/15; 40%). Mechanistically, these findings were associated with 
Figure 4. 
Differential effects of TA1 and IA1 on the immune system. (A and B): Secretome production (A) of SYN 
(resting), IA1 (MLR) and TA1 (mPEG-MLR) gave rise to unique immunomodulatory activity (B). While 
IA1 enhanced proinflammatory subsets and reduced Treg cells, TA1 enhanced Treg while reducing Teff 
subpopulations. (C) Attesting to the conserved nature of miRNA, murine TA1 and IA1 exerted significant, 
dose-dependent, immunomodulatory effects on resting human PBMC. The SYN secretome product had 
no substantive effects on T cell proliferation and differentiation. Data derived from Refs: [32–43] TA1 
administration induces a persistent tolerogenic state in immunocompetent mice. (D) As shown, CD4+Foxp3+ 
Treg cells remain elevated for ≥270 days following a SINGLE TA1 administration at age 7–8 weeks. In contrast, 
RNase-treated TA1 (to degrade the miRNA) had no immunomodulatory effect. Results shown are from a 
minimum of 8 animals per group Unpublished data.
Cells of the Immune System
8
a systemic alteration of the immune system as noted in Figure 5. In control NOD 
mice, the progression to diabetes was characterized by significantly elevated 
levels of most proinflammatory Teff (e.g., INF-γ+, Th17+, and IL-2+) lymphocytes 
and a corresponding decrease in regulatory subsets. In contrast, TA1 therapy 
dramatically and significantly blunted the expansion of Teff cells (as exempli-
fied by INF-γ+, Th17+, and IL-2+ lymphocytes; Figure 5A) relative to diabetic or 
nondiabetic control NOD mice coupled with a simultaneous increase in a broad 
range of tolerogenic/anergic regulatory T cell subsets (e.g., foxp3+, IL-10+, TGF-β+; 
Figure 5B) in the pancreatic lymph node. These studies also demonstrated that 
TA1 treated NOD mice had significant numbers of histologically normal pancreatic 
islets while no normal islets were identified in the untreated mice [40]. It is worth 
noting that all diabetic mice (control and TA1-treated) exhibited significantly 
lower levels of these tolerogenic cells than did the 30 week old nondiabetic (control 
or TA1) mice. Moreover, the effects of TA1-miRNA therapy were not localized 
to the pancreatic lymph node microenvironment. Analyses of the T cell subsets 
present in the spleen and brachial lymph node of control and TA1 treated NOD 
mice (diabetic and nondiabetic) similarly demonstrated dramatic changes in the 
Figure 5. 
The autoimmune disease of T1D process is mediated by a decrease in the Treg:Teff ratio and can be prevented 
by TA1 administration (top). Treatment with the TA1 miRNA product prevents the decrease and, in fact, 
significantly increases the Treg:Teff ratio. The increased Treg:Teff ratio is protective as evidenced by the finding 
that the majority of TA1 treated animals remained normoglycemic. Shown in the blue bars are the Treg:Teff 
ratio for TA1 treated mice who were diabetic (ratio of 70) and nondiabetic (ratio of 255). Mechanistically, 
TA1 immunotherapeutic significantly altered the expression of multiple proinflammatory (A) and tolerogenic/
anergic (B) T cell subsets. These changes were systemic in nature as shown by changes in not only the pancreatic 
lymph node but in other immune tissues (spleen and brachial lymph node). Diabetic tissues were harvested 
at time of conversion, nondiabetic tissues were harvested at week 30. Diabetic values are the mean ± SD of 12 
saline and 6 TA1 treated NOD mice. Nondiabetic results are the mean ± SD of 4 saline and 9 TA1 treated NOD 
mice. Derived from Ref. [40].
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Teff cell populations (Figure 5A, right) and tolerogenic T cells (Figure 5B, right). 
These findings demonstrate that miRNA-based TA1 therapeutic, directly targets 
the Treg:Teff ratio yielding a systemic protolerogenic state both in vivo (mouse) 
and in vitro (human and mouse) suggesting that this approach would be of utility 
in a broad range of autoimmune diseases. Furthermore, due to the persistence of 
the immunomodulatory activity in mice (Figure 4), TA1-like drugs could, poten-
tially, dramatically reduce the need for chronic administration of drugs.
6. Proinflammatory IA1: enhancing the immune response to cancer
T cells plays a critical role in the anticancer inflammatory responses. An effec-
tive anticancer proinflammatory T cell response is dependent upon the activation 
of Teff cells. Normally, T cells are activated upon ligation of their antigen recep-
tors with specific cognate antigens [68]. However, because of the low frequency 
of cancer antigen-specific lymphocytes, the immune response to cancers can be 
initially, and all too often remains, weak. While previous studies have attempted to 
enhance the anticancer T cell response using pan T cell mitogens (e.g., phytohemag-
glutinin; PHA), cytokines (e.g., IL-2), or monoclonal antibodies (e.g., anti-CD3 
and anti-CD28) the overly robust T cell response arising from these approaches 
often induced significant systemic toxicity leading to the suspension or abrogation 
of multiple clinical trials [69–74]. In contrast, in an allorecognition response only 
1–10% of T cells are alloreactive [75]. Hence, the IA1 therapeutic, derived from a 
bioreactor allorecognition response (MLR), is expected to activate endogenous T 
cells in a more controlled manner, with less toxicity.
To assess IA1’s ability to enhance the anticancer activity of resting PBMC, 
cells were treated for 24 hours with IA1 and overlaid on HeLa and SH-4 cancers 
cells. Cancer cell proliferation was then followed for 168 hours. Importantly, IA1 
exerted no toxicity to resting PBMC but, as shown in Figure 4, induced significant 
activation (e.g., proliferation) of resting CD3+ (CD4+ and CD8+) skewed towards 
proinflammatory subsets thus decreasing the Teff:Treg ratio. However, as predicted 
by the biology of the alloresponse, IA1-mediated T cell proliferation was much more 
restrained than that induced by the anti-CD3/anti-CD28 or PHA stimulation [43]. 
This finding suggests that the systemic toxicity, relative to pan T cell activators, 
should be greatly reduced. Crucially, IA1-activated PBMC demonstrated a potent 
inhibition of cancer cell (HeLa and SH-4 melanoma) proliferation relative to the 
resting PBMC (Figure 6). The anti-proliferation effect of IA1-activated PBMC was 
noted within ~12 hours vs. 4–5 days for resting cells. These findings demonstrate 
that miRNA-enriched therapeutics can be biomanufactured from the secretome and 
can induce a potent proinflammatory, anticancer, effect on resting lymphocytes.
The potential utility and use of IA1 in Adoptive Cell Therapy (ACT) is diagram-
matically shown in Figure 6. The bioproduction of IA1 is both inexpensive and rapid 
(5 days) and the IA1 can be stored for long periods (several months frozen in the lab-
oratory; data not shown). Moreover, neither IA1 or TA1 production actually requires 
donor specific tissues (PBMC) making these secretome-based therapeutics an “off-
the-shelf” immune adjuvant. Most importantly for patient care, ex vivo activation of 
lymphocytes is rapid (24 hours). The rapidity of this approach is in stark contrast to 
the weeks to months necessary for production and expansion of CAR-T cells. Hence, 
IA1 activation of autologous PBMC could be employed as a first line therapy or, 
potentially, be used as an immunotherapeutic bridge while CAR-T cells are produced. 
Due to the simplicity and low cost of the approach, multiple rounds could be used 
as necessary with large numbers of autologous PBMC employed. Indeed, due to the 
ability to infuse large numbers of IA1 treated autologous cells, enhanced recognition 
Cells of the Immune System
10
of not only the primary tumor but metastatic sites as well could be achieved thus 
improving long-term survival. Of note, similarly to our use of the tolerogenic TA1 in 
NOD mice (Figures 4 and 5), IA1 could be directly injected into the recipient yield-
ing a systemic proinflammatory reset of the immune system [40].
7. Conclusions
The immunomodulation of the endogenous immune system has become a 
major focus in treating a broad range of clinical conditions ranging from tissue/
organ engraftment, autoimmune disease and cancer therapy. While significant 
clinical advancements have been made in immunotherapy, substantial challenges 
remain. One target of interest is the biologic/clinical desire to induce a persistent 
systemic immunological reset that could reduce both the need for chronic therapy 
and reduce the potential toxicities associated with current immunomodulatory 
approaches. Recent studies have demonstrated that miRNA are key regulators 
of cellular processes involved in both tolerogenic and proinflammatory immune 
responses and mediate immune cell proliferation and differentiation. Using an 
alloresponse bioreactor secretome system we have demonstrated that miRNA-based 
therapeutics can be reproducibly manufactured that can systemically reorient the 
immune system to either a tolerogenic or proinflammatory state by simultaneously 
Figure 6. 
Schematic presentation of use and efficacy of the IA1 secretome therapeutic. Left panels: the enhanced efficacy 
of treated PBMC is supported by photomicrographs of allogenic PBMC responding to HeLa cells. As shown, 
after 72 hours incubation, resting (weak responders; left) PBMC show limited interaction when overlaid on 
HeLa cells. In contrast, the same PBMC, when treated for 24 hours with IA1, show a robust enhanced interaction 
(right) with the HeLa cell monolayer. Moreover, when IA1-treated PBMC are overlaid on SH-4 melanoma cells 
a greatly enhanced anti-cancer effect is noted relative to untreated PBMC. Shown are the growth profiles (as 
measured by electrical impedance) of SH-4 treated with either the SYN (derived from the secretome of resting 
PBMC) or IA1therapeutics. PBMC:SH-4 ratios included 50:1, 25:1 and 10:1. Right panels: bioreactor production 
of IA1 secretome is readily accomplished using an allogeneic MLR. Potential source materials include PBMC 
donors (A and B), autologous cells (dotted arrow), lymphocytic cell lines, or leukoreduction filters from blood 
collection bags. The secretome is collected at day 5 for processing into IA1 (Figure 4). IA1 is stable for months 
when aliquoted and frozen. Weak to absent immune response to both the primary tumor and metastatic sites 
allows for cancer progression. PBMC (D) from the patient can be treated ex vivo for 24 hours with IA1 and 
then reinfused into the individual where they show enhanced recognition and killing of the primary tumor and, 
potentially, improved immune surveillance at metastatic sites. Derived from Ref. [43].
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modulating both regulatory and effector T cell subsets thus skewing the Treg:Teff 
cell ratio to favor tolerance or inflammation. The tolerogenic TA1 therapeutic is 
derived from polymer-mediated immunocamouflage of the alloresponse reaction 
while the inflammatory IA1 preparation is derived from the alloresponse itself. The 
secretomes from these reactions are processed to maintain the miRNA within the 
secretome. In contrast to most miRNA therapeutic tactics, our approach has been 
to mimic the “complex pattern of miRNA expression” seen in protolerogenic or 
proinflammatory states. This “complex” approach was predicated by the inherent 
nature of miRNA bioregulation in that there is a low probability that altered expres-
sion of a single, or even a few, miRNA would exert a potent and definitive biological 
response. As shown, this approach successfully results in significant and, in mice, 
systemic and persistent changes to the immune system. The tolerogenic TA1 proved 
useful in reducing the onset and incidence of autoimmune diabetes in the NOD 
mouse while the proinflammatory IA1 therapeutic greatly enhanced the efficacy 
of human T cells to recognize and kill cancer cells without inducing the systemic 
inflammatory response seen with mitogens or monoclonal antibody (e.g., anti-
CD3/CD28) therapies. Moreover, this approach can simultaneously modulate both 
regulatory and effect T cell subtype. The successful development of this miRNA-
immunomodulatory approach may prove useful in facilitating organ engraftment, 
treating autoimmune disease and enhancing the endogenous anticancer response.
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